

Ministry of Health and Long-Term Care

Ontario Public Drug Programs

Drug Submission Status

Complete Streamlined Multiple-Source Submissions for Future Formulary Listing

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for listing on the Ontario Drug Benefit Formulary. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be listed as benefits in a future Formulary update. Final listing status will be communicated when the Formulary update is published on the Ministry website and via an OPDP Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Apotex Inc.	Apo-Letrozole	Femara	letrozole	2.5mg	FC tablet	02358514
Auro Pharma Inc.	Auro-Nevirapine	Viramune	nevirapine	200mg	tablet	02318601
Genmed, A Division of Pfizer Canada Inc.	GD-Sertraline	Zoloft	sertraline hydrochloride	25mg	capsule	02273683
Genmed, A Division of Pfizer Canada Inc.	GD-Sertraline	Zoloft	sertraline hydrochloride	50mg	capsule	02273691
Genmed, A Division of Pfizer Canada Inc.	GD-Sertraline	Zoloft	sertraline hydrochloride	100mg	capsule	02273705
Pharmascience Inc.	Pms-Bupropion SR	Wellbutrin SR	bupropion hydrochloride	100mg	FC ER tablet	02325373
Pharmascience Inc.	Pms-Diltiazem CD	Cardizem CD	diltiazem hydrochloride	120mg	CD capsule	02355752
Pharmascience Inc.	Pms-Diltiazem CD	Cardizem CD	diltiazem hydrochloride	180mg	CD capsule	02355760

Pharmascience Inc.	Pms-Diltiazem CD	Cardizem CD	diltiazem hydrochloride	240mg	CD capsule	02355779
Sandoz Canada Inc.	Sandoz Tamsulosin CR	Flomax CR	tamsulosin hydrochloride	0.4mg	ER tablet	02340208

Updated: January 28, 2011